Crisil Research

Crisil Research

In FY24, the SMEs were hit hard as a 25 per cent drop in cotton prices and weak RMG exports pulled down the industry revenue despite steady domestic demand

Updated On: 24 Mar 2025 | 11:38 PM IST

Indeed, as margins shrink, the smaller players are exiting, leading to market consolidation

Updated On: 25 Feb 2025 | 12:02 AM IST

Last financial year, the industry witnessed a sharp 10 per cent growth in revenue, driven by an 8 per cent year-on-year (Y-o-Y) increase in sugar prices and a steady 2 per cent rise in consumption

Updated On: 23 Jan 2025 | 11:28 PM IST

Amid the shifting sands of geopolitics, Russia remained India's top crude oil supplier accounting for 35 to 40 per cent of total imports

Updated On: 01 Jan 2025 | 11:15 PM IST

The RBI's increase in risk weights on bank lending to non-banking financial companies (NBFCs) and on unsecured loans has pruned credit growth in these segments

Updated On: 01 Jan 2025 | 12:18 AM IST

The key reason is patients continuing to favour large hospital chains on the back of pan-India insurance penetration increasing to 38-40 per cent from 23 per cent in FY15

Updated On: 31 Dec 2024 | 11:16 PM IST

A CRISIL Ratings study of the top 25 firms, accounting for 55 per cent of the Rs 14 trillion IT sector's revenue in fiscal 2024

Updated On: 30 Dec 2024 | 11:55 PM IST

Growth is expected to be stable on the supply side as well. With a stable outlook for both demand and supply, the year-to-sales indicator for inventory will continue to remain favourable

Updated On: 25 Dec 2024 | 10:23 PM IST

Rural demand had been subdued in the past few financial years owing to low farm profitability because of erratic monsoon and the outsized impact of the pandemic on rural incomes

Updated On: 24 Dec 2024 | 11:33 PM IST

As of October 2024, India's non-fossil base, including solar, wind, large-hydro and other renewables, surpassed 200 gigawatt (Gw)

Updated On: 24 Dec 2024 | 7:00 PM IST

Bulk drug exports are expected to see moderate increases, supported by volume growth from new launches, customised synthesis, and rising demand for complex drugs

Updated On: 24 Dec 2024 | 6:59 PM IST

The fund's assets under management rose to Rs 66,207 crore as of September 2024, up from Rs 30,724 crore in September 2021

Updated On: 23 Dec 2024 | 12:09 AM IST

The scheme aims for long-term capital growth by investing in a portfolio of equity securities while offering tax benefits under Section 80C of the Income-Tax Act, 1961

Updated On: 08 Dec 2024 | 11:30 PM IST

Over the past three years, the fund has consistently adhered to its mandate of investing in largecap and midcap stocks, with a strong preference for largecaps

Updated On: 17 Nov 2024 | 11:21 PM IST

In the past three years, the fund has dynamically adjusted its allocations across market capitalisations while predominantly investing in largecap stocks

Updated On: 27 Oct 2024 | 9:50 PM IST

Among the segment drivers, the replacement market is expected to clock 6-8 per cent on-year growth, following 7 per cent rise last financial year

Updated On: 22 Oct 2024 | 11:13 PM IST

The fund was exposed to 71 stocks during the three-year period, consistently holding seven stocks

Updated On: 13 Oct 2024 | 10:47 PM IST

Growth will be supported by resumption of deferred projects and new orders from key segments such as banking, financial services and insurance and manufacturing

Updated On: 30 Sep 2024 | 11:08 PM IST

The fund has three managers: Sunaina da Cunha, who has managed the fund since April 2017; Mohit Sharma, since August 2020; and Dhaval Joshi, since November 2022

Updated On: 29 Sep 2024 | 10:51 PM IST

As of June 2024, the fund's assets under management totalled Rs 56,469 crore, up from Rs 15,353 crore in June 2021

Updated On: 15 Sep 2024 | 10:19 PM IST